UNASSIGNED: To analyze the clinical characteristics and treatment outcomes of @entity455 , and determine which therapy is safe and effective.The data of @entity455 pediatric @entity1 who arrived at Beijing @entity1 's Hospital from January 2001 to December 2014 were analyzed retrospectively, including the influence of gender, age, clinical manifestation, diagnosis, treatment options, and outcomes. As to @entity7492 , the outcomes of different treatments and their adverse reactions were compared. As to @entity2695 and cutaneous @entity600 , the treatment effect of 595nm pulsed dye laser (PDL) is analyzed.A total number of 6459 cases of @entity455 were reclassified according to the 2014 ISSVA classification system. Among them, the gender ratio is 1:1.69, head-and-neck involved is 53.3%, the onset age within the first month is 72.4%, the age of initial encounter that younger than 6 months is 60.1%. The most common anomalies were @entity7492 (42.6%), @entity2695 (14.1%), and @entity600 (29.9%). In treating @entity7492 , laser shows the lowest adverse reactions rate significantly. @entity1169 shows a higher improvement rate than laser, glucocorticoids, glucocorticoids plus laser, and shows no significant difference with @entity1169 plus laser both in improvement rate and adverse reactions rate. The total improvement rate of 595nm PDL is 89.8% in treating @entity2695 and 46.7% in treating cutaneous @entity600 . The improvement rate and excellent rate of laser in treating cutaneous @entity600 are growing synchronously by increasing the treatment times, and shows no significant difference among different parts of lesion that located in a body. @entity455 possess a female predominance, and are mostly occurred in faces. Definite diagnosis is very important before treatment. In treating @entity7492 , @entity1169 is recommended as the first-line agent, and systemic use glucocorticoids should be considered when associated with serious complications. The 595nm PDL is effective in managing superficial @entity1462 in childhood, and could attempt to increase the treatment times to improve the outcomes.

Clinical Characteristics and Treatment Options of XXXX .

@entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol', 'Propranolol'] @entity455 :: ('MESH:D014652', 'Disease') :: ['Vascular anomalies', 'vascular anomalies'] @entity2695 :: ('MESH:D006391', 'Disease') :: ['congenital hemangiomas', 'spider angioma'] @entity7492 :: ('MESH:C535860', 'Disease') :: ['infantile hemangiomas', 'infantile hemangioma'] @entity600 :: ('MESH:D000014', 'Disease') :: ['capillary malformation', 'capillary malformations'] @entity1462 :: ('MESH:D054079', 'Disease') :: ['vascular malformations']
@entity455 :: (MESH:D014652,Disease) :: ['Infantile Vascular Anomalies']
